**
The Advertising Standards Authority (ASA) has taken significant action against the promotion of prescription-only weight loss medications on social media platforms, banning a total of 13 posts that used discount codes and referral links to entice users into purchasing these drugs. This move underscores the ongoing concerns regarding the legality and safety of advertising prescription medications directly to the public, particularly through informal social media channels.
Rise of Affiliate Marketing in Prescription Medication Promotion
In recent years, the rise of affiliate marketing schemes has blurred the lines between legitimate advertising and illegal promotion. Individuals have been sharing discount codes for various online pharmacies, including Voy, Zava, and MedExpress, often without understanding the regulatory implications. The ASA’s investigation revealed that several posts not only named specific medications such as Wegovy and Mounjaro but also used enticing hashtags and images to encourage followers to embark on their own weight-loss journeys.
One notable post, shared by the account stephenwilliamhair on 25 December 2024, featured an image of a man with text overlay stating, “A year ago today I was fat.” The accompanying caption invited followers to message for a 25% off voucher for Voy, highlighting how personal testimonials can effectively influence perceptions and behaviours around weight loss.
Regulatory Concerns and Responsibilities
The ASA has made it clear that the promotion of prescription medications via social media, whether by influencers, brands, or users, is illegal under current advertising regulations. Catherine Drewett, investigations manager at the ASA, emphasised the importance of adhering to these rules to protect the public from potentially harmful and irresponsible advertising practices. She stated, “Affiliate marketing is not a loophole,” indicating that both companies and individuals must ensure compliance with advertising standards.
Voy, which operated a “refer a friend” scheme offering discounts to new customers, was found to have control over the distribution of the discount codes. This responsibility extends to ensuring that all advertising activities are conducted within the law. Consequently, the ASA has mandated that these advertisements must not be repeated and has warned individuals against promoting prescription medications without appropriate authorisation.
Industry Responses and Future Implications
The response from the companies involved has varied. While Voy admitted that it had some control over how discount codes were shared, it argued that the offending posts were not directly under its management. Zava, on the other hand, denied any commercial relationship with the social media users who posted the promotions, clarifying that their discount codes apply to a broader range of products, not solely prescription medications.
In contrast, UK Meds Direct acknowledged that their affiliates had engaged in promotional activities that could be construed as illegal and took steps to rectify the situation once alerted by the ASA. Julian Beach, interim executive director at the Medicines and Healthcare products Regulatory Agency (MHRA), reiterated the necessity of clinical assessments before prescribing weight-loss medications, warning that the promotion of these drugs through informal channels undermines critical patient safeguards.
Why it Matters
The implications of this crackdown extend beyond regulatory compliance; they touch on broader public health concerns. As social media continues to influence health behaviours, the need for stringent oversight becomes increasingly vital. Misleading promotions can lead individuals to pursue unregulated and potentially dangerous treatments, ultimately putting their health at risk. The ASA’s actions serve as a reminder of the fine balance between marketing and ethical responsibility, advocating for a more conscientious approach to health-related advertising in the digital age.
